Original Contributions

Differential Involvement of Tyrosine and Serine/Threonine Kinases in Platelet Integrin αIIbβ3 Exposure

Ingeborg Hers, José Donath, Gijsbert van Willigen, Jan Willem N. Akkerman
https://doi.org/10.1161/01.ATV.18.3.404
Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18:404-414
Originally published March 1, 1998

Jump to

Abstract

Abstract—The relative contributions of protein tyrosine kinases (PTKs) and protein kinase C isoenzymes (PKCs), a family of serine/threonine kinases, in integrin αIIbβ3 (glycoprotein IIb/IIIa) exposure are the subject of much controversy. In the present study we measured the effect of the PTK inhibitor herbimycin A and the PKC inhibitor bisindolylmaleimide I on 125I-fibrinogen binding to αIIbβ3 and on aggregation/secretion induced by different agonists. Dose-response studies showed complete inhibition of αIIbβ3 exposure by 30 μmol/L (ADP stimulation) and 35 to 40 μmol/L (α-thrombin stimulation) herbimycin A. In contrast, inhibition of exposure by bisindolylmaleimide I varied from none (for ADP and epinephrine), to 30% (for platelet-activating factor), and to ≈80% (for α-thrombin). Studies with a submaximal dose of herbimycin A (≈50% inhibition of the ADP-response) and a maximal dose of bisindolylmaleimide I showed that optical aggregation had a similar sensitivity to the inhibitors as αIIbβ3 exposure with minimal interference by secreted ADP. Thus, the relative contributions of tyrosine and serine/threonine kinases in αIIbβ3 exposure and aggregation differ among the different agonists, with an exclusive role for PTKs in ADP- and epinephrine-induced responses and a role for both PTKs and PKCs in responses induced by platelet-activating factor and α-thrombin.

  • Received February 5, 1997.
  • Accepted November 11, 1997.

Platelet aggregation is mediated by the coupling of fibrinogen to integrin αIIbβ3 (ie, glycoprotein IIb/IIIa) via binding sites that are exposed when these cells are activated. Our understanding of the intracellular mechanisms that control the exposure of ligand-binding sites on platelet integrin αIIbβ3 is far from complete. A major stimulating pathway in platelets involves tyrosine kinases, which may signal to the processes mediating platelet-platelet contact and formation of focal adhesions.1 A second stimulating route involves hydrolysis of polyphosphoinositides and formation of diacylglycerol, inositol 1,4,5-tris-phosphate, and phosphatidic acid. Diacylglycerol activates PKC, whereas inositol 1,4,5-tris-phosphate mobilizes Ca2+, thereby inducing rearrangements of the plasma membrane and cytoskeleton that facilitate anchorage of αIIbβ3 and possibly exposure of the binding sites.1 2

There is uncertainty regarding the role of protein kinases in inside-out signaling to αIIbβ3. Platelet activation is accompanied by tyrosine phosphorylation of 60-, 64-, 75-, and 130-kDa proteins, a step that precedes ligand binding to αIIbβ3 and subsequent outside-in signaling through this integrin.3 4 One or more of these tyrosine phosphorylations may therefore function in the intracellular control of αIIbβ3, which accords with the effect of certain PTK inhibitors. For instance, genistein, erbstatin, and tyrphostins inhibit aggregation and secretion induced by α-thrombin, collagen, and PAF.5 6 7 8 9 10 The binding of fibrinogen and the activation-dependent antibody PAC-1 induced by α-thrombin and ADP is also abolished.11 In contrast, other studies could not confirm these observations and emphasized the poor specificity of these inhibitors.12 13 14

Serine/threonine phosphorylation might also contribute to the regulation of αIIbβ3. Activation of PKCs with phorbol esters, such as phorbol myristate acetate, exposes binding sites for fibrinogen and the activation-dependent antibody PAC-1 and induces aggregation.15 16 Bisindolylmaleimide derivatives, which block PKC activity, strongly reduce α-thrombin– and collagen-induced aggregation17 18 19 and α-thrombin–induced fibrinogen binding.20 The target of PKC appears to be the β3 subunit of the integrin, as phorbol myristate acetate–induced binding and 32 P incorporation correlate linearly20 and stimulation with α-thrombin increases the stoichiometry of β3 phosphorylation from 5±2% to 80±10%.20

In the course of our studies on αIIbβ3 control, we found that ADP and α-thrombin differed greatly in their sensitivity to inhibitors of protein kinases. Thus, we explored the relative contributions of tyrosine and serine/threonine phosphorylation in further detail, giving special attention to indirect modulation of αIIbβ3 by secreted ADP, formation of TxA2, and the correlation between αIIbβ3 exposure and optical aggregation responses.

Methods

Materials

Human α-thrombin, epinephrine, imipramine, indomethacin, BSA (RIA grade), and protein A–peroxidase were purchased from Sigma Chemical Co; staurosporine, ADP, PAF, PEP, PK, and the PKC inhibitor bisindolylmaleimide I (GF 109203X) were from Boehringer. Bisindolylmaleimide II and V, calphostin C, geldanamycin, tyrphostin A47, and PPACK were from Calbiochem. Sepharose 2B was obtained from Pharmacia Biotech and BSA (demineralized) from Organon Technika. Na[125I], with a specific activity of 629 GBq/mg, and 5-hydroxy[side chain-2-14C]tryptamine creatinine sulfate ([14C]-serotonin), with a specific activity of 1.85 to 2.29 GBq/mmol, were from Amersham International. [32P]Orthophosphate with a specific activity of 314 TBq/mmol was from New England Nuclear. FITC was obtained from Pierce Chemical Co; dPPA and herbimycin A were from Biomol Research Laboratories, and the anti-phosphotyrosine antibodies 4G10 and PY20 were from Upstate Biotechnology Inc. Fibrinogen (grade L) was from Chromogenix. FITC-labeled monoclonal mouse antibody to the platelet glycoprotein IIIa (β3) subunit was obtained from Dakopatts. FITC calibration beads (Quantum 24 series) were obtained from Flow Cytometry Standards Corp.

Platelet Isolation

Freshly drawn venous blood from healthy volunteers (with informed consent) who claimed not to have taken any medication in the previous 14 days was anticoagulated with 0.1 volume of 130 mmol/L trisodium citrate. Platelet-rich plasma was obtained by centrifugation (200g, 5 minutes, 22°C), and the platelets were isolated by gel filtration on a Sepharose 2B column equilibrated in Ca2+-free Tyrode’s solution (137 mmol/L NaCl, 2.68 mmol/L KCl, 0.42 mmol/L NaH2PO4, 1.7 mmol/L MgCl2, and 11.9 mmol/L NaHCO3, pH 7.2) containing 0.1% glucose and 0.2% BSA (demineralized). The platelet count was adjusted to 200×103/μL.

Preparation of 125I-Labeled Fibrinogen and FITC-Fibrinogen

Fibrinogen was made fibrin- and fibronectin-free by separation on a gelatin–Sepharose 4B column and radiolabeled with Na[125I] by a modified Iodo-Gen method. Details of these procedures have been described elsewhere.21 The labeling with FITC was performed as described.22

Platelet Aggregation

Gel-filtered platelets (200×103/μL) were preincubated with vehicle (DMSO), herbimycin A (5 minutes, 15 μmol/L), or bisindolylmaleimide I (1 minute, 5 μmol/L) with or without the ADP scavenger PEP/PK (14 mmol/L PEP, 150 U/mL PK). Suspensions were stirred (900 rpm) in the presence of fibrinogen (1 μmol/L) at 37°C. Subsequently, platelets were stimulated with 10 μmol/L ADP, 10 μmol/L epinephrine, 200 nmol/L PAF, or 0.2 U/mL α-thrombin, and aggregation was measured in a Chrono-Log Lumiaggregometer (Chrono-Log Corp) at 37°C. The agonist concentrations used in these experiments induced maximal aggregation of gel-filtered platelets. When α-thrombin was used as an agonist, 30 nmol/L PPACK was added 30 seconds after stimulation to prevent coagulation. Aggregation was measured as the change in light transmission. Quantitative data reflect the extent of aggregation at 5 minutes after stimulation.

Binding of 125I-Labeled Fibrinogen

Gel-filtered platelets (200×103/μL) were preincubated with different concentrations of the kinase inhibitors. Preincubation times and concentrations were as follows: for herbimycin A, 5 minutes, 15 and 30 μmol/L; geldanamycin, 10 minutes, 5 and 10 μmol/L; tyrphostin A47, 10 minutes, 300 and 500 μmol/L; bisindolylmaleimide I, II, and V, 1 minute, 5 μmol/L; and calphostin C, 30 minutes, 3 μmol/L at 22°C without stirring. Under these conditions the inhibitors completely blocked protein phosphorylation as established in dose-response studies on tyrosine phosphorylation and pleckstrin phosphorylation (data not shown). Platelets were stimulated with 200 nmol/L PAF, 10 μmol/L ADP, or 10 μmol/L epinephrine in the presence of 1 μmol/L 125I-fibrinogen or with 0.2 U/mL α-thrombin in the absence of 125I-fibrinogen. PPACK was added 3 minutes after stimulation with α-thrombin to prevent coagulation, whereas 125I-fibrinogen was added 2 minutes thereafter.

After a 15-minute incubation at 22°C with 125I-fibrinogen, each sample (in triplicate) of 200 μL was drawn, layered on top of 100 μL of 20% (wt/vol) sucrose in Ca2+-free Tyrode’s solution in microsedimentation tubes (Sarstedt), and centrifuged (12 000g, 4 minutes, 22°C) in a Beckman Microfuge E. The pellet was separated from the supernatant and counted for radioactivity in a gamma counter. The number of molecules bound per platelet was calculated from the radioactivity in the pellet fraction compared with the total radioactivity in the pellet plus supernatant. The data were corrected for nonspecific binding, defined as the binding of 125I-fibrinogen to unstimulated platelets (7232±3021 fibrinogen molecules per platelet), which was in the same range as in stimulated platelets in the presence of a 100-fold molar excess of nonradiolabeled fibrinogen.21

Binding of FITC-Labeled PAC-1, Anti-β3 Antibody, and Fibrinogen

Gel-filtered platelets (200×103/μL) were preincubated with vehicle (DMSO), herbimycin A (5 minutes, 15 or 30 μmol/L), or bisindolylmaleimide I or V (1 minute, 5 μmol/L) at 22°C. Platelets were stimulated with 0.2 U/mL α-thrombin in the presence of 40 μmol/L FITC-labeled-PAC-1 or 10 μg/mL FITC-labeled monoclonal antibody against the β3 subunit. After a 15-minute incubation in the dark, the platelets were diluted to 20×103/μL, fixed in Tyrode’s buffer containing 1% paraformaldehyde, and analyzed by flow cytometry (FACScan, Becton Dickinson). The data obtained with FITC–PAC-1 were corrected for nonspecific binding, defined as the binding of FITC–PAC-1 to unstimulated platelets (mean fluorescence intensity of 8±4).

For the fibrinogen-binding experiments, platelets were stimulated with 0.2 U/mL α-thrombin in the absence of FITC-fibrinogen. PPACK was added 3 minutes after stimulation to prevent coagulation, and 30 μmol/L FITC-fibrinogen (final concentration) was added 2 minutes thereafter. After a 15-minute incubation with FITC-labeled-fibrinogen in the dark at 22°C, platelets were fixed and analyzed as described. Fibrinogen binding was quantified by using FITC calibration beads. These beads emit a fluorescence intensity equivalent to a fixed number of FITC molecules in suspension, from which a standard curve is prepared that relates the median channel number of beads to the number of fluorescein equivalents per bead. The number of fibrinogen molecules bound per platelet was calculated from the median channel number obtained from each platelet sample divided by the known fluorescence-to-fibrinogen ratio (see Reference 2222 for details). The data were corrected for nonspecific binding, defined as the binding of FITC-fibrinogen to unstimulated platelets (mean fluorescence intensity of 35±9).

Measurement of Protein Tyrosine Phosphorylation

Gel-filtered platelets (200×103/μL) were preincubated with vehicle (DMSO), different concentrations of herbimycin A (5-minute preincubation), or bisindolylmaleimide I (1 minute, 5 μmol/L) at 22°C. Subsequently platelets were stimulated with 0.2 U/mL α-thrombin, 10 μmol/L ADP, or 10 μmol/L dPPA in the presence of 1 μmol/L fibrinogen for 15 minutes. Aliquots of the stimulated platelets were lysed in 10× lysis buffer (10% Nonidet P40, 5% n-octylglucoside, 1% SDS, 10 mmol/L orthovanadate, 10 mmol/L PMSF, 200 μg/mL soybean trypsin inhibitor, 50 mmol/L N-ethylmaleimide, and 100 mmol/L benzamidine). The lysate was incubated for 3 hours at 4°C with the monoclonal antibody PY20. Subsequently the antigen-antibody complex was precipitated with 5 μL of protein A–Sepharose beads (45 minutes, 22°C). After extensive washing in 1× lysis buffer (1% Nonidet P40, 0.5% n-octylglucoside, 0.1% SDS, 137 mmol/L NaCl, 2.68 mmol/L KCl, 0.42 mmol/L NaH2PO4, 1.7 mmol/L MgCl2, 11.9 mmol/L NaHCO3, and 0.2% BSA), the bound protein was extracted from the Sepharose beads by boiling for 5 minutes in a twofold-concentrated Laemmli electrophoresis sample buffer. Proteins were separated by SDS–7.5% PAGE and electrophoretically transferred (1 hour, 100 V) to nitrocellulose membranes in 25 mmol/L Tris–192 mmol/L glycine (pH 8.3) and 20% methanol (vol/vol) using a Bio-Rad mini trans-blot system (Bio-Rad). The blots were blocked with PBS containing 4% BSA (RIA grade) for 1 hour at room temperature and subsequently incubated (16 hours, 4°C) with the anti-phosphotyrosine antibody 4G10. After extensive washing in PBS containing 1% Tween and 1% BSA (RIA grade), the blots were incubated with peroxidase-labeled protein A (2 μg/mL, 2 hours, 4°C). Subsequently the blots were treated with Renaissance chemiluminescence Western blot reagent and exposed to Renaissance autoradiography film (Dupont NEN Research Products).

Measurement of PKC Activity

Platelets were labeled with 3.7 MBq of carrier-free [32P]Pi/mL of platelet-rich plasma for 1 hour at 37°C. Platelet suspensions were acidified to pH 6.5, centrifuged, and resuspended in HEPES-Tyrode’s buffer (145 mmol/L NaCl, 5 mmol/L KCl, 0.5 mmol/L Na2HPO4, 1 mmol/L MgSO4, and 10 mmol/L HEPES, pH 7.2) containing 0.1% glucose. Labeled platelets were incubated for 1 minute with bisindolylmaleimide I (5 μmol/L) or for 5 minutes with herbimycin A (15 and 40 μmol/L) before stimulation with 0.2 U/mL α-thrombin. Samples were collected 15 minutes after stimulation, transferred into threefold-concentrated Laemmli sample buffer, and boiled for 5 minutes prior to SDS-PAGE (11%). Gels were stained with Coomassie Brilliant Blue, and the radioactive bands were visualized by autoradiography.

[14C]Serotonin Secretion

Platelets were labeled in platelet-rich plasma with 1 μmol/L [14C]serotonin for 30 minutes at 37°C. Subsequently the platelet suspension was acidified to pH 6.5 and washed on a Sepharose 2B column equilibrated in Ca2+-free Tyrode’s solution. The experiments were performed at 22°C in the presence of 2.5 μmol/L imipramine to prevent reuptake of secreted serotonin by the platelets. Samples were collected 15 minutes after addition of the agonists in 0.15 vol of 1.035 mol/L formaldehyde in saline (4°C) to stop serotonin secretion. After centrifugation (10 000g, 2 minutes, 22°C), the supernatants were counted according to standard procedures. The data are expressed as the percentage of maximal secretable [14C]serotonin (α-thrombin, 5 U/mL, 15 minutes, 22°C).

Presentation of Data

Data are expressed as mean±SD from 3 to 6 (aggregation), 4 to 6 (125I-fibrinogen binding), and 3 (FITC-labeled anti-β3 monoclonal antibody–, FITC-fibrinogen–, and FITC–PAC-1 binding) experiments. Statistical significance was determined by Student’s t test for unpaired data and considered significant at P<.05.

Results

Role of PTKs and PKC in Fibrinogen Binding to αIIbβ3

Fig 1A⇓ shows that herbimycin A dose-dependently inhibited 125I-fibrinogen binding to αIIbβ3 induced by ADP (10 μmol/L) and α-thrombin (0.2 U/mL). Half-maximal inhibition was reached at ≈17 μmol/L herbimycin A for ADP and 28 μmol/L herbimycin A for α-thrombin; at respective concentrations of 30 and 40 μmol/L, complete blockade was observed. Similar inhibition was found with the PTK inhibitors geldanamycin, a benzoquinoid antibiotic related to herbimycin A, and tyrphostin A47, a structurally different PTK inhibitor (Table 1⇓). Geldanamycin reduced both ADP- and α-thrombin–induced ligand binding at 5 μmol/L and completely inhibited ligand binding at 10 μmol/L (Table 1⇓). Tyrphostin A47 dose-dependently inhibited both ADP- and α-thrombin–induced fibrinogen binding, with maximal inhibition at 350 μmol/L.

Figure 1.
Figure 1.

Effect of herbimycin A and bisindolylmaleimide I on ligand binding to αIIbβ3 and protein phosphorylation. For fibrinogen binding, gel-filtered platelets (200×103/μL) were preincubated for 5 minutes with various concentrations of herbimycin A (A) or for 1 minute with various concentrations of bisindolylmaleimide I (B) and subsequently stimulated with 10 μmol/L ADP (▪–▪) in the presence of 125I-fibrinogen or with 0.2 U/mL α-thrombin (▴–▴) in the absence of 125I-fibrinogen. PPACK and 125I-fibrinogen were added at 3 and 5 minutes, respectively, after α-thrombin. Specific binding was measured after a 15-minute incubation in the presence of 125I-fibrinogen at 22°C. Data (mean±SD, n=4) are expressed as the percentage of maximal binding in the absence of inhibitors. For protein phosphorylation, unlabeled platelets (C) or 32P-labeled platelets (D) (200×103/μL) were treated as described above. Protein tyrosine phosphorylation (C) and pleckstrin phosphorylation (D) were analyzed after 15 minutes in the presence of fibrinogen (1 μmol/L). bis I indicates bisindolylmaleimide I, 5 μmol/L; herb A, herbimycin A.

View this table:
Table 1.

Effect of Different PTK and PKC Inhibitors on ADP- and α-Thrombin–Induced Fibrinogen Binding

The PKC inhibitor bisindolylmaleimide I, which interacts with the ATP binding site of PKC, had no effect on ADP-induced binding up to a concentration of 5 μmol/L (Fig 1B⇑). In contrast, α-thrombin–induced binding was dose-dependently reduced by bisindolylmaleimide I and was maximal at 5 μmol/L (Fig 1B⇑). Similar results were found with bisindolylmaleimide II and the structurally different PKC inhibitor calphostin C (Table 1⇑). Bisindolylmaleimide II differs from bisindolylmaleimide I in that the dimethylaminopropyl side group has been replaced by methylpyrrolidinoethyl. At 5 μmol/L it had no effect on ADP-induced fibrinogen binding but strongly reduced α-thrombin–induced binding. Bisindolylmaleimide V, the inactive bisindolylmaleimide in which the side group is absent, had no effect. Calphostin C, which interacts with the regulatory domain of PKC, only slightly reduced ADP-induced binding, whereas it strongly interfered with α-thrombin–induced binding. Noteworthy is the fact that all PKC inhibitors left 20% to 30% of the ligand binding intact, whereas the PTK inhibitors induced complete inhibition. Together these data suggest that PTKs play a role in both ADP- and α-thrombin–induced αIIbβ3 exposure. In contrast, a role for PKCs appears restricted to α-thrombin–induced αIIbβ3 control.

To assess whether herbimycin A and bisindolylmaleimide I efficiently blocked PTKs and PKCs under the conditions of the binding experiments, tyrosine-phosphorylated proteins (Fig 1C⇑) and phosphorylated pleckstrin (Fig 1D⇑) were analyzed. α-Thrombin increased the phosphorylation of proteins of 75 and 130 kDa. Bands representing 60- and 64-kDa proteins were already phosphorylated in resting platelets and showed no further increase. In addition, some tyrosine phosphorylation was observed in proteins of 84 and 90 to 100 kDa. Herbimycin A strongly reduced phosphorylation of the 75-kDa band, whereas phosphorylation of the 84-, 90- to 100-, and 130-kDa bands was inhibited to a lesser extent. Bisindolylmaleimide I (5 μmol/L) slightly inhibited α-thrombin–induced tyrosine phosphorylation. ADP induced a weaker increase in tyrosine phosphorylation, mainly in proteins of 60, 64, 75, and 130 kDa. Again the phosphorylation was dose-dependently reduced by herbimycin A. Bisindolylmaleimide I failed to affect the tyrosine phosphorylation of these proteins. In contrast to ADP, α-thrombin (0.2 U/mL) induced phosphorylation of the 47-kDa protein pleckstrin, which is a major substrate for PKCs. Bisindolylmaleimide I (5 μmol/L) completely blocked this phosphorylation, whereas 15 to 40 μmol/L herbimycin A had no effect.

Effect of PTK and PKC Inhibition on Aggregation and Fibrinogen Binding

Because the dose-response studies suggested that the relative contributions of PTKs and PKCs in αIIbβ3 control differed among different agonists, 125I-fibrinogen binding studies were repeated with ADP and α-thrombin and compared with those evoked by epinephrine and PAF. To assess whether differences in αIIbβ3 regulation also affected platelet aggregation, the binding data (established at 22°C without stirring) were compared with concurrently run aggregation curves (established at 37°C with stirring) with platelets from the same donor. Herbimycin A was used at a submaximal concentration of 15 μmol/L, since differences in sensitivity among agonists were most apparent at low concentrations of the inhibitor (Fig 1A⇑). This concentration reduced ADP-induced fibrinogen binding to ≈50% of that of untreated suspensions. The sensitivity to bisindolylmaleimide I was measured at an optimal concentration of 5 μmol/L. In addition, the effect of staurosporine (1 μmol/L) was measured, which is known to block both PTKs and PKCs.23 Some studies were performed in the presence of the ADP scavenger mixture PEP/PK to evaluate the role of secreted ADP, as exocytosis is greatly impaired by inhibitors of PKC.17 18 As expected, all agonists induced secretion of [14C]serotonin in platelet suspensions stirred at 37°C (data not shown). In contrast, under ligand-binding conditions serotonin secretion was only 3±1% (n=4) of maximal in the presence of ADP, epinephrine, and PAF but 82±3% (n=7) of maximal in α-thrombin–treated platelets.

Suspensions stimulated with ADP (Fig 2A⇓) showed rapid first- and second-wave aggregation and binding of 51 243±4760 (n=5) fibrinogen molecules per platelet (control). Herbimycin A reduced aggregation to 26% and fibrinogen binding to 58% of controls. Bisindolylmaleimide I inhibited aggregation (P<.05), but ligand binding remained unchanged. A combination of bisindolylmaleimide I and herbimycin A did not further reduce aggregation and fibrinogen binding compared with herbimycin A alone (P>.05). Finally, staurosporine suppressed aggregation to 27% and ligand binding to 10% of controls.

Figure 2.
Figure 2.

Role of protein kinases in aggregation and ligand binding to αIIbβ3 induced by different agonists. For aggregations (all panels, tracings and bar graphs; open bars), gel-filtered platelets were stirred (900 rpm) at 37°C in the presence of 1 μmol/L fibrinogen and 10 μmol/L ADP (A), 10 μmol/L epinephrine (B), 200 nmol/L PAF (C), or 0.2 U/mL α-thrombin (D) (arrows) after preincubation with (a) DMSO (control), (b) PEP/PK, (c) herbimycin A (5 minutes, 15 μmol/L), (d) bisindolylmaleimide I (1 minute, 5 μmol/L), (e) bisindolylmaleimide I and PEP/PK, (f) bisindolylmaleimide I and herbimycin A, or (g) staurosporine (1 minute, 1 μmol/L). PPACK was added 30 seconds after α-thrombin stimulation to prevent coagulation. Data (mean±SD, n≥3) are expressed as the percentage of maximal light transmission 5 minutes after stimulation in the absence of inhibitors. For fibrinogen binding (all panels, bar graphs; open bars), gel-filtered platelets (200×103/μL) were incubated with the same inhibitors and subsequently stimulated with ADP (A), epinephrine (B), or PAF (C) in the presence of 125I-fibrinogen or with 0.2 U/mL α-thrombin (D) in the absence of 125I-fibrinogen. PPACK was added 3 minutes and 125I-fibrinogen 5 minutes after α-thrombin stimulation. Specific binding was measured after a 15-minute incubation in the presence of 125I-fibrinogen at 22°C. Data (mean±SD, n≥3) are expressed as the percentage of maximal binding in the absence of inhibitors (100% values: ADP, 51 243±4760; epinephrine, 31 067±4230; PAF, 56 852±4430; and α-thrombin, 94 430±8993 molecules fibrinogen per platelet).

Epinephrine-induced responses (Fig 2B⇑) showed a sensitivity similar to the two inhibitors as seen with ADP. This agonist induced biphasic aggregation and binding of 31 067±4230 fibrinogen molecules per platelet (control). Removal of ADP by PEP/PK inhibited aggregation (P<.05) but had no effect on ligand binding. This finding is in agreement with the absence of serotonin secretion under ligand-binding conditions. Herbimycin A reduced aggregation to 33% and ligand binding to 52% of controls. In contrast, both responses were insensitive to bisindolylmaleimide I (P>.05). A combination of bisindolylmaleimide I and PEP/PK further reduced aggregation (P<.05), although no significant additive effect was seen on fibrinogen binding. Bisindolylmaleimide I had no effect on aggregation or ligand binding of herbimycin A–treated platelets (P>.05). Again, staurosporine strongly suppressed both aggregation (to 26% of control) and ligand binding (to 9%).

PAF induced aggregation and fibrinogen binding (56 852±4430 molecules per platelet, control) as shown in Fig 2C⇑. Again, the effect of the inhibitors was roughly similar to that observed for ADP and epinephrine, but an important difference was the effect of bisindolylmaleimide I, which reduced aggregation to 42% and ligand binding to 68% of control. A combination of this PKC inhibitor with PEP/PK reduced aggregation further (P<.05) without affecting ligand binding. A combination of herbimycin A and bisindolylmaleimide I inhibited ligand binding (to 47%), which is stronger inhibition than that seen with herbimycin A alone. Staurosporine reduced aggregation and binding to 50% and 18%, respectively.

A further increase in sensitivity to bisindolylmaleimide I was seen with stimulation by α-thrombin (Fig 2D⇑), which was accompanied by a decrease in sensitivity to herbimycin A. This agonist induced strong and rapid aggregation and binding of 93 430±8993 molecules of fibrinogen per platelet (control). PEP/PK reduced the aggregation response to 83% (P<.05), whereas ligand binding was not affected. Thus, although α-thrombin induced secretion in the binding experiments, the liberated ADP hardly interfered with ligand binding. Suspensions treated with herbimycin A showed no decrease in aggregation, but ligand binding was slightly inhibited (to 79%, P<.05). In contrast, bisindolylmaleimide I suppressed aggregation almost completely (to 18%) and inhibited ligand binding to 26%. A combination of this PKC inhibitor with PEP/PK did not further reduce aggregation and ligand binding. Herbimycin A had no significant effect on PKC-independent aggregation (P=.26) but further reduced ligand binding (P<.05). Almost complete inhibition was also seen with staurosporine. Together these data reveal that ADP- and epinephrine-induced ligand binding to αIIbβ3 depends on PTKs but not on PKCs, whereas PAF- and α-thrombin–induced binding depends on both types of kinases. The aggregation curves reflect the inhibitor sensitivity for ligand binding; in addition, they illustrate the contribution of PKC-mediated secretion and further enhancement by released ADP.

To evaluate a possible role for PTKs downstream of PKC activation, platelets were stimulated with the PKC β–activator dPPA (Fig 3⇓). dPPA-induced fibrinogen binding (40 700±8644, n=8) was unaffected by PEP/PK but completely blocked by bisindolylmaleimide I (7±3%, n=7). Surprisingly, a submaximal concentration of herbimycin A reduced fibrinogen binding to 47±16% of control (n=4) and a maximal concentration reduced fibrinogen binding to 6±3% of control (n=4), suggesting involvement of PTKs downstream of PKC activation. In agreement with this observation, dPPA induced tyrosine phosphorylation of proteins with apparent molecular weights of 60, 64, 72, 84, and 130 kDa, an event that was completely blocked by bisindolylmaleimide I and reduced by increasing concentrations of herbimycin A (Fig 3A⇓ and B). As expected, bisindolylmaleimide I completely blocked dPPA-induced pleckstrin phosphorylation, whereas herbimycin A had no effect (data not shown).

Figure 3.
Figure 3.

Role of protein kinases in dPPA-induced ligand binding to αIIbβ3. Gel-filtered platelets (200×103/μL) were incubated with inhibitors as noted in Fig 2⇑ and subsequently stimulated with 10 μmol/L dPPA in the presence of 125I-fibrinogen. Specific binding was measured after a 15-minute incubation in the presence of 125I-fibrinogen at 22°C. Data (mean±SD, n≥3) are expressed as the percentage of maximal binding in the absence of inhibitors (100% value: 40 700±8644). bis I indicates bisindolylmaleimide I; herb A, herbimycin A; and stauro, staurosporine. A: Gel-filtered platelets (200×103/μL) were treated as described above. Protein tyrosine phosphorylation was analyzed after 15 minutes in the presence of fibrinogen (1 μmol/L).

Role of Tx Formation

The fact that bisindolylmaleimide I inhibited ADP-induced aggregation but not ligand binding agrees with the concept that aggregating platelets produce TxA2, which further enhances platelet responses via activation of PKC. To assess the sensitivity of the inhibitors in the absence of this pathway, aggregation studies were repeated with indomethacin-treated platelets. Table 2⇓ illustrates that the difference in sensitivity of ADP- and α-thrombin–stimulated platelets to inhibitors of PTKs and PKCs was preserved. ADP-induced aggregation was strongly reduced by herbimycin A (P<.05), whereas bisindolylmaleimide I had no effect (P>.05). A combination of both inhibitors did not further reduce aggregation (P>.05). In contrast, bisindolylmaleimide I strongly inhibited α-thrombin–induced aggregation (P<.05). Also, herbimycin A reduced aggregation, although the effect was less pronounced. The combination of inhibitors completely blocked α-thrombin–induced aggregation.

View this table:
Table 2.

Role of Tx Formation

Role of PTKs and PKCs in Expression of Internal αIIbβ3

Unlike ADP, epinephrine, and PAF, which activate only surface-bound αIIbβ3, α-thrombin is known to express a second pool of αIIbβ3 complexes located in the open canalicular system and α-granules.24 This difference is illustrated by the almost-twofold higher fibrinogen binding induced by α-thrombin compared with that induced by ADP, PAF, or epinephrine (Fig 2⇑). To investigate the role of PTKs and PKCs in the surface expression of internal αIIbβ3, the accessibility of αIIbβ3 for an anti-β3 antibody was compared with the number of exposed αIIbβ3. Fig 4⇓ shows that α-thrombin induced an almost-twofold increase in the binding of an FITC–anti-β3, revealing the surface expression of the internal pool. This expression was almost completely blocked by 5 μmol/L bisindolylmaleimide I, whereas the inactive bisindolylmaleimide V and herbimycin A had no significant effect.

Figure 4.
Figure 4.

Surface expression of the internal pool of αIIbβ3. Gel-filtered platelets (200×103/μL) were preincubated with DMSO (control), 5 μmol/L bisindolylmaleimide I or V (respectively bis I and bis V), or 15 or 30 μmol/L herbimycin A (herb A) and stimulated with 0.2 U/mL α-thrombin in the presence of an FITC-labeled antibody against the β3-subunit or FITC–PAC-1 or in the absence of FITC-fibrinogen. After a 15-minute incubation with antibody, platelets were fixed and the fluorescence analyzed by flow cytometry. For fibrinogen binding, PPACK was added 3 minutes after stimulation and FITC-fibrinogen was added 5 minutes after stimulation. After a 15-minute incubation with FITC-fibrinogen, platelets were fixed and analyzed as described. Hatched bar represents binding to unstimulated platelets. Data are expressed as percentage of maximal median fluorescence with α-thrombin (mean±SD, n=4). (100% FITC-fibrinogen binding=mean fluorescence intensity of 155±20=88 570±11 428 molecules fibrinogen per platelet, 100% FITC–anti-β3 binding=mean fluorescence intensity of 196±14, 100% FITC–PAC-1 binding=130±12).

α-Thrombin–induced binding of FITC-fibrinogen was almost completely prevented by bisindolylmaleimide I, in line with findings for the binding of 125I-fibrinogen (Fig 2D⇑). Again, the inactive bisindolylmaleimide V had no effect. Herbimycin A had little effect on FITC-fibrinogen binding at 15 μmol/L but strongly interfered with binding at 30 μmol/L, which also accords with the binding data for 125I-fibrinogen. Similar results were found with PAC-1, an antibody against the activated conformation of αIIbβ3. Bisindolylmaleimide I strongly inhibited α-thrombin–induced binding of FITC–PAC-1, whereas bisindolylmaleimide V had no effect. Again, a dose-dependent reduction was seen in the presence of herbimycin A.

Analysis of [14C]serotonin secretion was in line with these observations. Bisindolylmaleimide I reduced dense granule secretion from 82±3% to 3±1%. Herbimycin A had no significant effect at 15 μmol/L (83±10%, P>.05) and only slightly inhibited secretion at 30 μmol/L (67±5%, n=5, P<.05). Together these data indicate that the surface expression of internal αIIbβ3 requires activation of PKCs but is independent of PTK activity. Instead, both PTKs and PKCs are required for the exposure of ligand-binding sites on both pools of αIIbβ3 complexes, as demonstrated by the lower binding of FITC-fibrinogen and FITC–PAC-1 compared with the binding of FITC–anti-β3.

Discussion

The present study applied inhibitors of PTKs and PKCs to define the roles of these kinases in the exposure of ligand-binding sites on integrin αIIbβ3 by different agonists. Together the data show that there is a dominant role for PTKs and little involvement of PKCs in sites exposed by ADP and epinephrine, a role for both types of kinases in sites exposed by PAF, and a dominant role for PKCs in sites exposed by α-thrombin, with a smaller but still significant contribution of PTKs.

It was important to select an appropriate PTK inhibitor, since different inhibitors show diverse effects on signal transduction mechanisms6 12 and nonspecific effects cannot always be ruled out. Genistein is a potent antagonist of the Tx receptor in addition to its PTK-inhibitory effect.13 25 Erbstatin inhibits phosphoinositide metabolism, PKC, and serotonin secretion.6 Tyrphostin AG213 inhibits virtually all steps in platelet signal transduction, eg, Ca2+ mobilization, phosphoinositide metabolism,5 26 and activation of phospholipases C and D5 9 27 and PKC,9 as well as serotonin secretion,5 9 and inhibits the enzymatic activity of GTP-utilizing proteins.28 At present, herbimycin A might be the inhibitor of choice, as it blocks kinases of the src family29 and pp72syk 30 but leaves PKC activation (Reference 3131 and this study) and TxA2 formation31 unchanged. Fukazawa et al32 demonstrated that herbimycin A selectively binds to the kinase domain of PTKs, thereby inhibiting access to ATP.

Nonreceptor tyrosine kinases in platelets include the src family members pp60src, pp61fyn, pp62yes, pp61,hck and pp54/58lyn 33,34; pp72syk; and pp125FAK. Only pp60src and pp72syk are activated in the absence of fibrinogen binding and are therefore candidates for control of αIIbβ3 under the conditions of our binding experiments. pp60src is activated within seconds,35 36 37 38 while pp72syk is rapidly phosphorylated and activated by α-thrombin,4 39 collagen,4 ADP,4 and PAF.40 pp72syk is further activated on ligand binding to αIIbβ3.38 Herbimycin A inhibited ligand binding induced by all agonists studied, although α-thrombin–induced binding was less sensitive than that induced by ADP, epinephrine, and PAF. Because the binding of 125I-fibrinogen was analyzed after 15 minutes (22°C, nonstirring), it is possible that outside-in signaling after fibrinogen binding affects PTK activation at later stages of incubation. However, essentially similar results were obtained with PAC-1, an antibody directed against the exposed conformation that binds to αIIbβ3 without inducing signal generation. pp72syk is the only platelet tyrosine kinase identified at present whose activity is directly stimulated by αIIbβ3 occupancy.4 41 Fibrinogen binding also leads to integrin-dependent phosphorylation of proteins such as p140 and p50–68, which is most likely initiated by receptor cross-linking.42 At present it is uncertain whether phosphorylation of these proteins signals back to αIIbβ3. Phosphorylation of pp125FAK and the recently reported tyrosine phosphorylation of the β3 subunit only occur after platelet aggregation43 and therefore might take part in postaggregatory events such as cytoskeleton attachment and clot retraction.

In general, the sensitivity to herbimycin A seen in the binding studies is also observed in optical aggregation experiments, although the latter is more strongly reduced with weak agonists. This may reflect an effect on postoccupancy signaling events that take part in the stabilization of aggregation. As expected there is a slight inhibition by PEP/PK, illustrating the contribution of secreted ADP, but the sensitivity to herbimycin A seen in the fibrinogen-binding studies remains preserved. Thus, herbimycin A inhibited the platelet aggregation induced by all agonists studied, but the α-thrombin–induced response was less sensitive than the responses induced by ADP, epinephrine, and PAF. This finding is in contrast to those of Schoenwaelder et al,31 who found no effect of herbimycin A on α-thrombin–induced aggregation even after a 24-hour incubation with the inhibitor.

Bisindolylmaleimide I (GF 109203X) is an inhibitor of the different PKC isozymes α, β1, β2, and γ in both purified enzyme systems and intact cells.17 Its potency and specificity make it a suitable PKC inhibitor for the present studies. Although it slightly inhibited ADP-induced platelet aggregation via an inhibitory effect on TxA2-mediated responses, PAF- and α-thrombin–induced responses were more strongly reduced. This difference in sensitivity for the PKC inhibitor was even more evident in the ligand-binding studies, wherein ADP- and epinephrine-induced fibrinogen binding was unaffected by the inhibitor. PKC activation by ADP or epinephrine has been the subject of much controversy. ADP induces aggregation without the formation of inositol trisphosphate44 or an increase in cytosolic Ca2+,45 46 and pleckstrin is only slightly phosphorylated.20 Pulcinelli et al47 found no effect of the PKC inhibitor Ro 31–8220 on ADP-induced fibrinogen binding, in agreement with the present study, but their conclusion that the same is true for other agonists is refuted by the present data. Other studies confirmed the role of PKC in α-thrombin–induced aggregation and found inhibition by bisindolylmaleimide derivatives Ro 31–754948 and Ro 31–8220.18 However, a much greater reduction was found with bisindolylmaleimide I (Reference 1717 and this study), possibly because Ro 31–8220 stimulates other kinases independent of its ability to inhibit PKC.49 In support of a role for PKCs in αIIbβ3 exposure, Gabbeta et al50 reported on a patient with normal numbers of αIIbβ3 integrins but diminished pleckstrin phosphorylation after platelet activation, suggesting lowered PKC activity. Platelets from this patient showed reduced binding of the activation-dependent antibody PAC-1 after stimulation with α-thrombin and PAF but not with ADP.50

Our results are consistent with a role for PKCs in PAF- and α-thrombin–induced inside-out signaling, leading to exposure of ligand-binding sites on αIIbβ3 on the platelet surface. It may be argued, however, that the reduction in α-thrombin–induced ligand binding and platelet aggregation is due to impaired surface expression of internal αIIbβ3 from the α-granules and the open canalicular system. Indeed, bisindolylmaleimide I completely blocked the surface expression of internal αIIbβ3 and reduced the binding of an anti-β3 antibody to the range of that for the external pool. The binding of fibrinogen and PAC-1 was well below that range, indicating that PKC activity is required for the exposure of surface αIIbβ3 as well as for the recruitment of internal αIIbβ3.

The bisindolylmaleimide I–insensitive αIIbβ3 exposure observed with PAF and α-thrombin was further reduced by herbimycin A. Also staurosporine, a potent inhibitor of both PTKs and PKCs,23 51 induced a further reduction than did bisindolylmaleimide I alone. This suggest that PKCs only partially contribute to αIIbβ3 exposure by these agonists and that the essential component of the response is mediated by PTKs. In favor of independent roles for PTKs and PKCs is the early wave of tyrosine phosphorylation that is similar for all agonists, whether or not they activate PKCs.3 4 52 53 Protein phosphorylation under ligand-binding conditions partly supports this conclusion. Herbimycin A did not interfere with pleckstrin phosphorylation, in agreement with studies by Schoenwaelder et al.31 However, bisindolylmaleimide I reduced the overall level of α-thrombin–induced tyrosine phosphorylation, whereas ADP-induced tyrosine phosphorylation was hardly effected. Since tyrosine phosphorylation was determined under ligand-binding conditions (15 minutes after stimulation), this might reflect a role for PKC in the later stages of tyrosine phosphorylation. Indeed, early tyrosine phosphorylation has been shown to be unaffected by PKC inhibitors.54 The PKC β-activator dPPA induced tyrosine phosphorylation and exposed αIIbβ3, and both responses were inhibited by herbimycin A. Phorbol ester triggers tyrosine phosphorylation of several proteins similar to those phosphorylated after α-thrombin stimulation.3 Phosphorylation at Ser-12 by PKC might increase the substrate affinity of pp60src.35 Thus, activated PKC is unable to expose αIIbβ3 in the absence of tyrosine kinase activity. In previous studies we showed that ligand-binding sites on αIIbβ3 exposed by α-thrombin remain accessible, whereas sites exposed by ADP gradually closed. Inhibition of PKC rapidly closed the binding sites exposed by α-thrombin, suggesting a role for PKC in sustained exposure of ligand-binding sites on αIIbβ3.20

The present results, in combination with published data, can be best explained by assuming the following model (Fig 5⇓). Platelet agonists activate PTKs, but the degree of PKC activation differs among different agonists. PTKs shift surface αIIbβ3 molecules from the closed conformation (αIIbβ30) to the exposed conformation (αIIbβ3*), allowing ligand binding. In the absence of ligands, the integrin rapidly returns to the closed conformation.55 PKCs play three roles in αIIbβ3 control: first, they activate PTKs; second, they make the internal pool of αIIbβ3 available from α-granules and surface-connecting tubules during the secretion response; and third, they directly phosphorylate the β3-chain and prevent its return to the closed formation.

Figure 5.
Figure 5.

Model depicting regulation of αIIbβ3 exposure by protein kinases. Following stimulation by an agonist, PTKs and PKCs are activated. PTK activation (1) appears a general property of platelet agonists; PKC activation (2) differs among agonists. Direct activation by PKC (3) can replace step (1). PTKs convert the closed integrin (αIIbβ30) to the exposed configuration (αIIbβ3*), which in the absence of ligand rapidly recloses, probably due to dephosphorylation by protein tyrosine phosphatases (PTPs). Depending on the degree of PKC activation, internal αIIbβ3 is made available (4) and the β3-chain is phosphorylated (5), which opposes its return to the closed configuration. Dephosphorylation by Ser/Thr protein phosphatases of the 1-type converts the integrin to the closed conformation. (s) indicates surface.

Selected Abbreviations and Acronyms

dPPA=12-deoxyphorbol-13-phenylacetate-20-acetate
PAF=platelet-activating factor
PEP=phospho(enol)pyruvate
PK=pyruvate kinase
PKC=protein kinase C
PPACK=d-phenylalanyl-l-prolyl-l-arginine chloromethyl ketone
PTK=protein tyrosine kinase
Tx=thromboxane

Acknowledgments

This study was supported in part by a grant from the Netherlands Thrombosis Foundation (No. 92002).

References

  1. ↵
    Fox JEB, Lipfert L, Clark EA, Reynolds CC, Austin CD, Brugge JS. On the role of the platelet membrane skeleton in mediating signal transduction: association of GP IIb-IIIa, pp60c-src, pp62c-yes, and the p21ras GTPase-activating protein with the membrane skeleton. J Biol Chem. 1993;268:25973–25984.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Rotman A. Proteins: actin transformations. In: Holmsen H, ed. Platelet Responses and Metabolism. Boca Raton, Fla: CRC Press Inc; 1987:245–256.
  3. ↵
    Bachelot C, Cano E, Grelac F, Saleun S, Druker BJ, Levy-Toledano S, Fischer S, Rendu F. Functional implications of tyrosine protein phosphorylation in platelets: simultaneous studies with different agonists and inhibitors. Biochem J. 1992;284:923–928.
  4. ↵
    Clark EA, Shattil SJ, Ginsberg MH, Bolen J, Brugge JS. Regulation of the protein tyrosine kinase pp72syk by platelet agonists and the integrin αIIbβ3. J Biol Chem. 1994;269:28859–28864.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Guinebault C, Payrastre B, Sultan C, Mauco G, Breton M, Levy-Toledano S, Plantavid M, Chap H. Tyrosine kinases and phosphoinositide metabolism in thrombin-stimulated human platelets. Biochem J. 1993;292:851–856.
  6. ↵
    Salari H, Duronio V, Howard SL, Demos M, Jones K, Reany A, Hudson AT, Pelech SL. Erbstatin blocks platelet activating factor-induced protein-tyrosine phosphorylation, polyphosphoinositide hydrolysis, PKC activation, serotonin secretion and aggregation of rabbit platelets. FEBS Lett. 1990;263:104–108.
    OpenUrlCrossRefPubMed
  7. ↵
    Dhar A, Paul AK, Shukla SD. Platelet-activating factor stimulation of tyrosine kinase and its relationship to phospholipase C in rabbit platelets: studies with genistein and monoclonal antibody to phosphotyrosine. Mol Pharmacol. 1990;37:519–525.
    OpenUrlAbstract
  8. ↵
    Asahi M, Yanagi S, Ohta S, Inazu T, Sakai K, Takeuchi F, Taniguchi T, Yamamura H. Thrombin-induced human platelet aggregation is inhibited by protein-tyrosine kinase inhibitors, ST638 and genistein. FEBS Lett. 1992;309:10–14.
    OpenUrlCrossRefPubMed
  9. ↵
    Rendu F, Eldor A, Grelac F, Bachelot C, Gazit A, Gilon C, Levy-Toledano S, Levitzki A. Inhibition of platelet activation by tyrosine kinase inhibitors. Biochem Pharmacol. 1992;44:881–888.
    OpenUrlCrossRefPubMed
  10. ↵
    Dillon AMR, Heath MF. The effects of tyrphostins B42 and B46 on equine platelet function and protein tyrosine phosphorylation. Biochem Biophys Res Commun. 1995;212:595–601.
    OpenUrlCrossRefPubMed
  11. ↵
    Furman MI, Grigoryev D, Bray PF, Dise KR, Goldschmidt-Clermont PJ. Platelet tyrosine kinases and fibrinogen receptor activation. Circ Res. 1994;75:172–180.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Feinstein MB, Pumiglia K, Lau L-F. Tyrosine phosphorylation in platelets: its regulation and possible roles in platelet functions. Adv Exp Med Biol. 1993;344:129–148.
    OpenUrlPubMed
  13. ↵
    Nakashima S, Koike T, Nozawa Y. Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A2-mediated human platelet responses. Mol Pharmacol. 1991;39:475–480.
    OpenUrlAbstract
  14. ↵
    Ozaki Y, Yatomi Y, Jinnai Y, Kume S. Effects of genistein, a tyrosine kinase inhibitor, on platelet functions: genistein attenuates thrombin-induced Ca2+ mobilization in human platelets by affecting polyphosphoinositide turnover. Biochem Pharmacol. 1993;46:395–403.
    OpenUrlCrossRefPubMed
  15. ↵
    Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem. 1987;262:992–1000.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Van Willigen G, Akkerman JWN. Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIb-IIIa complex of human platelets. Biochem J. 1991;273:115–120.
  17. ↵
    Toullec D, Pianetti P, Coste H, Bellevergue P, Grand Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991;266:15771–15781.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Walker TR, Watson SP. Synergy between Ca2+ and protein kinase C is the major factor in determining the level of secretion from human platelets. Biochem J. 1993;289:277–282.
  19. ↵
    Watson SP, Blake RA, Lane T, Walker TR. The use of inhibitors of protein kinases and protein phosphatases to investigate the role of protein phosphorylation in platelet activation. Adv Exp Med Biol. 1993;344:105–118.
    OpenUrlPubMed
  20. ↵
    Van Willigen G, Hers I, Gorter G, Akkerman JWN. Exposure of ligand-binding sites on platelet integrin αIIB/β3 by phosphorylation of the β3 subunit. Biochem J. 1996;314:769–779.
  21. ↵
    Kloprogge E, Akkerman JWN. Platelet-activating factor (PAF-acether) induces high and low-affinity binding of fibrinogen to human platelets via independent mechanisms. Biochem J. 1986;240:403–412.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med. 1994;123:728–740.
    OpenUrlPubMed
  23. ↵
    Ruegg UT, Burgess GM. Staurosporine, K-252, and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci. 1989;6:218–220.
  24. ↵
    Woods V Jr, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complexes which may be accessible to some but not other extracellular proteins. J Biol Chem. 1986;261:15242–15251.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    McNicol A. The effects of genistein on platelet function are due to thromboxane receptor antagonism rather than inhibition of tyrosine kinase. Prostaglandins Leukot Essent Fatty Acids. 1993;48:379–384.
    OpenUrlCrossRefPubMed
  26. ↵
    Yatomi Y, Ozaki Y, Satoh K, Kume S. Synthesis of phosphatidylinositol 3,4-bisphosphate is regulated by protein-tyrosine phosphorylation but the p85α subunit of phosphatidylinositol 3-kinase may not be a target for tyrosine kinases in thrombin-stimulated human platelets. Biochim Biophys Acta. 1994;1212:337–344.
    OpenUrlPubMed
  27. ↵
    Martinson EA, Scheible S, Presek P. Inhibition of phospholipase D of human platelets by protein tyrosine kinase inhibitors. Cell Mol Biol (Noisy-le-grand).. 1994;40:627–634.
    OpenUrlPubMed
  28. ↵
    Wolbring G, Hollenberg MD, Schnetkamp PPM. Inhibition of GTP-utilizing enzymes by tyrphostins. J Biol Chem. 1994;269:22470–22472.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Uehara Y, Fukazawa H. Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases. Methods Enzymol. 1991;201:370–379.
    OpenUrlCrossRefPubMed
  30. Fujii C, Yanagi S, Sada K, Nagai K, Taniguchi T, Yamamura H. Involvement of protein-tyrosine kinase p72syk in collagen-induced signal transduction in platelets. Eur J Biochem. 1994;226:243–248.
    OpenUrlPubMed
  31. ↵
    Schoenwaelder SM, Jackson SP, Yuan Y, Teasdale MS, Salem HH, Mitchell CA. Tyrosine kinases regulate the cytoskeletal attachment of integrin αIIbβ3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin polymers. J Biol Chem. 1994;269:32479–32487.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Fukazawa H, Uehara Y, Murakami Y, Mizuno S, Hamada M, Takeuchi T. Labeling of v-Src and BCR-ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism. FEBS Lett. 1994;340:155–158.
    OpenUrlCrossRefPubMed
  33. Huang M-M, Bolen JB, Barnwell JW, Shattil SJ, Brugge JS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci U S A. 1991;88:7844–7848.
    OpenUrlAbstract/FREE Full Text
  34. Horak ID, Corcoran ML, Thompson PA, Wahl LM, Bolen JB. Expression of p60fyn in human platelets. Oncogene. 1990;5:597–602.
    OpenUrlPubMed
  35. ↵
    Liebenhoff U, Brockmeier D, Presek P. Substrate affinity of the protein tyrosine kinase pp60c-src is increased on thrombin stimulation of human platelets. Biochem J. 1993;295:41–48.
  36. ↵
    Wong S, Reynolds AB, Papkoff J. Platelet activation leads to increased c-src kinase activity and association of c-src with an 85-kDa tyrosine phosphoprotein. Oncogene. 1992;7:2407–2415.
    OpenUrlPubMed
  37. ↵
    Clark EA, Brugge JS. Redistribution of activated pp60c-src to integrin-dependent cytoskeletal complexes in thrombin-stimulated platelets. Mol Cell Biol. 1993;13:1863–1871.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Clark EA, Shattil SJ, Brugge JS. Regulation of protein tyrosine kinases in platelets. Trends Biochem Sci. 1994;19:464–469.
    OpenUrlCrossRefPubMed
  39. ↵
    Taniguchi T, Kitagawa H, Yasue S, Yanagi S, Sakai K, Asahi M, Ohta S, Takeuchi F, Nakamura S, Yamamura H. Protein-tyrosine kinase p72syk is activated by thrombin and is negatively regulated through Ca2+ mobilization in platelets. J Biol Chem. 1993;268:2277–2279.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Rezaul K, Yanagi S, Sada K, Taniguchi T, Yamamura H. Protein-tyrosine kinase p72syk is activated by platelet activating factor in platelets. Thromb Haemost. 1994;72:937–941.
    OpenUrlPubMed
  41. ↵
    Clark EA, Trikha M, Markland FS, Brugge JS. Structurally distinct disintegrins contortrostatin and multisquamatin differentially regulate platelet tyrosine phosphorylation. J Biol Chem. 1994;269:21940–21943.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Huang M-M, Lipfert L, Cunningham M, Brugge JS, Ginsberg MH, Shattil SJ, Huang MM. Adhesive ligand binding to integrin αIIBβ3 stimulates tyrosine phosphorylation of novel protein substrates before phosphorylation of pp125FAK. J Cell Biol. 1993;122:473–483.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Law DA, Nannizzi-Alaimo L, Phillips DR. Outside-in integrin signal transduction αIIbβ3 (GP IIb-IIIa) tyrosine phosphorylation induced by platelet aggregation. J Biol Chem. 1996;271:10811–10815.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Sweatt JD, Blair IA, Cragoe EJ, Limbird LE. Inhibitors of Na+/H+ exchange block epinephrine- and ADP-induced stimulation of human platelet phospholipase C by blockade of arachidonic acid release at a prior step. J Biol Chem. 1986;261:8660–8666.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Packham MA, Livne A-A, Ruben DH, Rand ML. Activation of phospholipase C and protein kinase C has little involvement in ADP-induced primary aggregation of human platelets: effects of diacylglycerols, the diacylglycerol kinase inhibitor R59022, staurosporine and okadaic acid. Biochem J. 1993;290:849–856.
  46. ↵
    Pulcinelli FM, Daniel JL, Riondino S, Gazzaniga PP, Salganicoff L. Fibrinogen binding is independent of an increase in intracellular calcium concentration in thrombin degranulated platelets. Thromb Haemost. 1995;73:304–308.
    OpenUrlPubMed
  47. ↵
    Pulcinelli FM, Ashby B, Gazzaniga PP, Daniel JL. Protein kinase C activation is not a key step in ADP-mediated exposure of fibrinogen receptors on human platelets. FEBS Lett. 1995;364:87–90.
    OpenUrlCrossRefPubMed
  48. ↵
    Hashimoto Y, Togo M, Tsukamoto K, Horie Y, Watanabe T, Kurokawa K. Protein kinase C-dependent and -independent mechanisms of dense granule exocytosis by human platelets. Biochim Biophys Acta. 1994;1222:56–62.
    OpenUrlPubMed
  49. ↵
    Beltman J, McCormick F, Cook SJ. The selective protein kinase C inhibitor, Ro-31–8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase. J Biol Chem. 1996;271:27018–27024.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Gabbeta J, Yang X, Sun L, McLane MA, Niewiarowski S, Rao AK. Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Blood. 1996;87:1368–1376.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M, Caravatti G, Matter A. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer. 1989;5:851–856.
    OpenUrl
  52. ↵
    Sargeant P, Farndale RW, Sage SO. ADP- and thapsigargin-evoked Ca2+ entry and protein-tyrosine phosphorylation are inhibited by the tyrosine kinase inhibitors genistein and methyl-2,5-dihydroxycinnamate in fura-2-loaded human platelets. J Biol Chem. 1993;268:18151–18156.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Oda A, Druker BJ, Smith M, Salzman EW. Inhibition by sodium nitroprusside or PGE1 of tyrosine phosphorylation induced in platelets by thrombin or ADP. Am J Physiol. 1992;262:C701–C707.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Falet H, Rendu F. Calcium mobilisation controls tyrosine protein phosphorylation independently of the activation of protein kinase C in human platelets. FEBS Lett. 1994;345:87–91.
    OpenUrlCrossRefPubMed
  55. ↵
    Kloprogge E, Mommersteeg M, Akkerman JWN. Kinetics of platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced fibrinogen binding to human platelets. J Biol Chem. 1986;261:11071–11076.
    OpenUrlAbstract/FREE Full Text
View Abstract

This Issue

Jump to

Article Tools

Share this Article

  • Email
  • Differential Involvement of Tyrosine and Serine/Threonine Kinases in Platelet Integrin αIIbβ3 Exposure
    Ingeborg Hers, José Donath, Gijsbert van Willigen and Jan Willem N. Akkerman
    Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18:404-414, originally published March 1, 1998
    https://doi.org/10.1161/01.ATV.18.3.404
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...